Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

Compare

10,656 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRSP Analyst Ratings

Moderate Buy

13 Buy

7 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Crispr

Therapeutics AG

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$70.33

▲(23.65% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $70.33 with a high forecast of $105.00 and a low forecast of $40.00. The average price target represents a 23.65% change from the last price of $56.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.17,56.23384615384616,60.29769230769231,64.36153846153846,68.42538461538462,72.48923076923077,76.55307692307693,80.61692307692307,84.68076923076923,88.74461538461539,92.80846153846153,96.87230769230769,100.93615384615384,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.17,53.566923076923075,54.963846153846156,56.36076923076923,57.75769230769231,59.15461538461538,60.55153846153846,61.94846153846154,63.34538461538462,64.74230769230769,66.13923076923076,67.53615384615385,68.93307692307692,{"y":70.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.17,51.23384615384616,50.29769230769231,49.361538461538466,48.425384615384615,47.48923076923077,46.55307692307692,45.61692307692308,44.68076923076923,43.744615384615386,42.808461538461536,41.87230769230769,40.93615384615384,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$70.33

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alec Stranahan

Bank of America Securities

$93

Buy

63.50%

Upside

Reiterated

12/08/25

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)We maintain our Buy rating and $93 PO.

Edward Tenthoff

Piper Sandler

$105

Buy

84.60%

Upside

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO), PROCEPT BioRobotics (NASDAQ: PRCT) and Crispr Therapeutics AG (NASDAQ: CRSP)We reiterate our Overweightrating and $105 price target.

William Pickering

Bernstein

$43

Hold

-24.40%

Downside

Reiterated

12/01/25

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Geulah Livshits

Chardan Capital

$74

Buy

30.10%

Upside

Reiterated

11/25/25

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (NASDAQ: PMN) and Crispr Therapeutics AG (NASDAQ: CRSP)

Mitchell Kapoor

H.C. Wainwright

$65→$80

Buy

40.65%

Upside

Reiterated

11/14/25

H.C. Wainwright Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)Two Heart-Focused Blockbusters From One Clinical Platform; Reiterate Buy – we reiterate our Buy rating and 12‐month price target of $80.

Yigal Nochomovitz

Citi

$87→$77

Buy

35.37%

Upside

Reiterated

11/12/25

Crispr Therapeutics price target lowered to $77 from $87 at CitiCrispr Therapeutics price target lowered to $77 from $87 at Citi

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Crispr Therapeutics AG (NASDAQ: CRSP) and Upstream Bio, Inc. (NASDAQ: UPB)

William Maughan

Clear Street

$52→$50

Hold

-12.10%

Downside

Reiterated

11/11/25

Crispr Therapeutics price target lowered to $50 from $52 at Clear StreetCrispr Therapeutics price target lowered to $50 from $52 at Clear Street

Gena Wang

Barclays

$56

Hold

-1.55%

Downside

Reiterated

11/11/25

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

Brian Cheng

J.P. Morgan

$70→$69

Buy

21.31%

Upside

Reiterated

11/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (NYSE: AMN) and Crispr Therapeutics AG (NASDAQ: CRSP)We maintain OW with Dec-2026 PT of $70.

Jack Allen

Robert W. Baird

$52→$44

Hold

-22.64%

Downside

Reiterated

11/11/25

Crispr Therapeutics price target lowered to $44 from $52 at BairdCrispr Therapeutics price target lowered to $44 from $52 at Baird

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

$95

Buy

67.02%

Upside

Reiterated

11/11/25

Oppenheimer Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)We update our model with actuals and maintain Outperform.

Tyler Van Buren

TD Cowen

$40

Hold

-29.68%

Downside

Reiterated

11/10/25

Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/10/25

Promising Phase I Results of CTX310 Justify Buy Rating for CRISPR Therapeutics

Gil Blum

Needham

$81→$80

Buy

40.65%

Upside

Reiterated

11/10/25

Promising Efficacy of Crispr Therapeutics' CTX310 in Dyslipidemia Treatment Drives Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alec Stranahan

Bank of America Securities

$93

Buy

63.50%

Upside

Reiterated

12/08/25

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)We maintain our Buy rating and $93 PO.

Edward Tenthoff

Piper Sandler

$105

Buy

84.60%

Upside

Reiterated

12/08/25

William Pickering

Bernstein

$43

Hold

-24.40%

Downside

Reiterated

12/01/25

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Geulah Livshits

Chardan Capital

$74

Buy

30.10%

Upside

Reiterated

11/25/25

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (NASDAQ: PMN) and Crispr Therapeutics AG (NASDAQ: CRSP)

Mitchell Kapoor

H.C. Wainwright

$65→$80

Buy

40.65%

Upside

Reiterated

11/14/25

Yigal Nochomovitz

Citi

$87→$77

Buy

35.37%

Upside

Reiterated

11/12/25

Crispr Therapeutics price target lowered to $77 from $87 at CitiCrispr Therapeutics price target lowered to $77 from $87 at Citi

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Crispr Therapeutics AG (NASDAQ: CRSP) and Upstream Bio, Inc. (NASDAQ: UPB)

William Maughan

Clear Street

$52→$50

Hold

-12.10%

Downside

Reiterated

11/11/25

Crispr Therapeutics price target lowered to $50 from $52 at Clear StreetCrispr Therapeutics price target lowered to $50 from $52 at Clear Street

Gena Wang

Barclays

$56

Hold

-1.55%

Downside

Reiterated

11/11/25

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

Brian Cheng

J.P. Morgan

$70→$69

Buy

21.31%

Upside

Reiterated

11/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (NYSE: AMN) and Crispr Therapeutics AG (NASDAQ: CRSP)We maintain OW with Dec-2026 PT of $70.

Jack Allen

Robert W. Baird

$52→$44

Hold

-22.64%

Downside

Reiterated

11/11/25

Crispr Therapeutics price target lowered to $44 from $52 at BairdCrispr Therapeutics price target lowered to $44 from $52 at Baird

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

$95

Buy

67.02%

Upside

Reiterated

11/11/25

Oppenheimer Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)We update our model with actuals and maintain Outperform.

Tyler Van Buren

TD Cowen

$40

Hold

-29.68%

Downside

Reiterated

11/10/25

Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/10/25

Promising Phase I Results of CTX310 Justify Buy Rating for CRISPR Therapeutics

Gil Blum

Needham

$81→$80

Buy

40.65%

Upside

Reiterated

11/10/25

Promising Efficacy of Crispr Therapeutics' CTX310 in Dyslipidemia Treatment Drives Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

1 Month

xxx

Success Rate

13/22 ratings generated profit

Average Return

+8.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +8.54% per trade.

3 Months

xxx

Success Rate

12/20 ratings generated profit

Average Return

+5.17%

reiterated a xxx

rating 16 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.17% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

12/22 ratings generated profit

Average Return

+9.38%

reiterated a buy rating 2 months ago

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +9.38% per trade.

2 Years

xxx

Success Rate

12/22 ratings generated profit

Average Return

+5.60%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +5.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRSP has received 19 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. CRSP average Analyst price target in the past 3 months is 70.33.

Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.18 with a range of -$1.67 to -$0.75. The previous quarter’s EPS was -$1.17. CRSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $5.66M with a range of $500.00K to $25.00M. The previous quarter’s sales results were $889.00K. CRSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CRSP has Performed in-line its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?

Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 70.33.

What is CRSP’s upside potential, based on the analysts’ average price target?

Crispr Therapeutics has 23.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRSP a Buy, Sell or Hold?

Crispr Therapeutics has a consensus rating of Moderate Buy which is based on 13 buy ratings, 7 hold ratings and 0 sell ratings.

What is Crispr Therapeutics’s price target?

The average price target for Crispr Therapeutics is 70.33. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $40.00. The average price target represents 23.65% Increase from the current price of $56.88.

What do analysts say about Crispr Therapeutics?

Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of CRSP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

CRSP Analyst Ratings

CRSP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crispr Therapeutics AG

CRSP Analyst Recommendation Trends

CRSP Financial Forecast

CRSP Earnings Forecast

CRSP Sales Forecast

CRSP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts